## Publications († Co-first author, * Corresponding author)

(1) **Wang Zikang**, Wang Wanhe*, and Leung Chung-Hang*. (2024) [Strategies for Developing Cancer Theranostics Approaches](https://www.eurekaselect.com/article/131687). _Recent Pat Anti-canc_, 19 (2), 130–136. (Invited by [Prof. CHEN Zhesheng](https://www.stjohns.edu/academics/faculty/zhe-sheng-chen))

(2) Li Guodong†, Ko Chung-Nga†, **Wang Zikang**, Chen Feng, Wang Wanhe*, Ma Dik-Lung* and Leung Chung-Hang*. (2023). [Interference reduction isothermal nucleic acid amplification strategy for COVID-19 variant detection](https://www.sciencedirect.com/science/article/pii/S0925400522016495?via%3Dihub#fig0030). _Sens. Actuators B Chem_, 377, 133006.


<h4 style="margin:0 10px 0;">In-Progress Manuscripts († Co-first author, * Corresponding author)</h4> 

(1) Li Guodong†, **Wang Zikang†**, Wang Wanhe* and Leung Chung-Hang*. BRD4 short isoform: an emerging hallmark of aggressive cancers. (2023) (**Submitted**)

(2) Leung Chung-Hang*, Wang Wanhe*, **Wang Zikang†**, et al. Multi-color cell imaging of cereblon using immunomodulatory imide drug (IMiD) labeling iridium(III) complexes. (Thesis project, ready for submission soon)

(3) Zhang Yuqing†, **Wang Zikang†**, [Bian Ying](https://sklqrcm.um.edu.mo/ying-bian/)*. The emerging role of a novel grading system to evaluate environmental information disclosure (EID) performance: empirical analysis of Chinese listed pharmaceutical companies. (2024) (**Submitted**)

**P.S.** Manuscript is available upon reasonable request.
